Please assess the completion status of the following clinical trial:

Trial Title: Comparing Ticagrelor Versus Clopidogrel on Microcirculation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of informed consent prior to any study specific procedures~* All patients with ACS scheduled for PCI will be eligible, assuming their ability to understand the character and individual consequences of participation as well as giving written informed consent.~* Be able to understand and comply with the requirements of the study, as judged by the investigator.~Exclusion Criteria:~* History of intracranial bleeding~* Severe hepatic impairment~* Active pathologic bleeding~* Hypersensitivity to ticagrelor or any of the excipients~* Liver cirrhosis greater than or equal to Child class B~* Decreased serum platelet level (≤ 100,000/uL)~* Life expectancy ≤ 1 year~* Need for chronic oral anticoagulant therapy~* Patients with known bleeding diathesis or coagulation disorder~* History of previous intracranial bleed at any time, gastrointestinal bleed within the past 6 months, or major surgery within 30 days.~* Ischemic stroke within the previous 14 days~* Renal failure requiring dialysis or anticipated need for dialysis during the course of the study~* Concern for inability of the patient to comply with study procedures and/or follow up~* Unable to give informed consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Ticagrelor (Type: EXPERIMENTAL): Ticagrelor 90mg, twice a day
- Clopidogrel (Type: ACTIVE_COMPARATOR): Clopidogrel 75mg, once a day

Based on this trial design, predict the completion outcome and termination type (if applicable).